2095628-21-8

2095628-21-8 structure

Name: Multi-kinase-IN-2
Chemical Name: Multi-kinase-IN-2
CAS Number: 2095628-21-8
Molecular Formula: C₃₄H₃₅N₅O₃
Molecular Weight: 561.67
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2022-08-31 10:35:35
Modify Date: 2024-09-22 10:48:22
Multi-kinase-IN-2 (compound 7h) is an orally active and potent angiokinase inhibitor. Multi-kinase-IN-2 exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and FGFR-1, as well as LYN and c-KIT kinases. Multi-kinase-IN-2 significantly attenuates phosphorylation of AKT and ERK proteins. Multi-kinase-IN-2 induces cell apoptosis. Multi-kinase-IN-2 shows anticancer activity[1].

Name	Multi-kinase-IN-2

Description	Multi-kinase-IN-2 (compound 7h) is an orally active and potent angiokinase inhibitor. Multi-kinase-IN-2 exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and FGFR-1, as well as LYN and c-KIT kinases. Multi-kinase-IN-2 significantly attenuates phosphorylation of AKT and ERK proteins. Multi-kinase-IN-2 induces cell apoptosis. Multi-kinase-IN-2 shows anticancer activity[1].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> PDGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Src Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FGFR Signaling Pathways >> PI3K/Akt/mTOR >> Akt Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Kit
Target	VEGFR-3:6.3 ± 0.5 nM (IC50) VEGFR-2:6.5 ± 0.9 nM (IC50) VEGFR-1:31 ± 2.1 nM (IC50) PDGFRα:7.0 ± 0.1 nM (IC50) PDGFRβ:9.9 ± 0.7 nM (IC50) FGFR1:23 ± 2.5 nM (IC50) pAKT
In Vitro	Multi-kinase-IN-2 (compound 7h) (0-10 μM, 14 days) potently inhibits colony formation of HT-29, MKN74, and HepG2 cancer cells[1]. Multi-kinase-IN-2 (0-3 μM, 24 h) significantly attenuates phosphorylation of AKT and ERK proteins[1]. Multi-kinase-IN-2 (0-3 μM, 72 h) induces apoptosis of HT-29, MKN74, and HepG2 cell[1]. Cell Proliferation Assay[1] Cell Line: HT-29, HepG2, and MKN74 cells Concentration: 0, 0.2, 0.5, 1, and 2 μM or 0, 0.3, 1, 3, and 10 μM Incubation Time: 14 days Result: Exhibited excellent activity in inhibition of colony formations in a dose-dependent manner, with remarkable activity at 1 µM concentration. Western Blot Analysis[1] Cell Line: HT-29 and HepG2 Concentration: 0, 0.2, 0.5, 1, and 2 μM or 0, 0.3, 1, 3, and 10 μM Incubation Time: 24 h Result: Suppressed the phosphorylation of AKT (Ser473) in a dose-dependent manner with a significant inhibition of ERK (Thr202/Tyr204) phosphorylation at 3 μM. Apoptosis Analysis[1] Cell Line: HT-29, MKN74, and HepG2 cells Concentration: 0, 0.3, 1, and 3 μM Incubation Time: 72 h Result: Triggered severe apoptosis of HT-29, MKN74, and HepG2 cells in a dose-dependent manner.
In Vivo	Multi-kinase-IN-2 (compound 7h) (100 mg/kg, Orally, once daily for 18 days) displays mild inhibition of tumor growth in mice[1]. Animal Model: Female nu/nu mice (4-6 weeks old, HT-29 human colon cancer xenograft model)[1] Dosage: 100 mg/kg Administration: Orally, once daily for 18 days Result: Displayed mild inhibition of tumor growth, with tumor growth inhibition (TGI) value of 13.39%.
References	[1]. Qin M, et al. Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity. Bioorg Med Chem. 2020 Jun 1;28(11):115486.

Molecular Formula	C₃₄H₃₅N₅O₃
Molecular Weight	561.67

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

2095628-21-8	2091950-43-3
2470807-67-9	2573071-18-6
2101241-90-9	501693-48-7
778274-97-8	1024168-48-6
1446324-02-2	1414938-22-9
1678527-90-6	865086-06-2
5771-59-5	1248234-22-1
1487353-23-0	1250292-88-6
870099-69-7	1248059-28-0
1340025-49-1	194019-20-0